Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping

Abstract excerpt

Between 20% and 50% of cardiovascular patients treated with clopidogrel, an anti-P2Y12 drug, display high on-treatment platelet reactivity (HTPR) and are not adequately protected from major adverse cardiovascular events (MACE). Despite a minor influence of the CYP2C19*2 genetic variant on the pharmacodynamic response to clopidogrel (5% to 12%) and a limited or absent value for predicting stent thrombosis and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antiplatelet Therapy and Cardiovascular Diseases
• Share to Venous Thromboembolism Diagnosis and Management